The FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug that targets aggressive tumours with a mutation known as MET.
It’s never good news when a drug firm posts an “update” about a phase 3 trial, and Bristol-Myers Squibb’s PR team have had to issue news of another trial disappointment from the misfiring c
An investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year after the FDA agreed to expedite development and review in a tough to treat form
Five years AstraZeneca became an oncology trailblazer by getting the first PARP inhibitor class drug Lynparza, approved by the FDA for certain ovarian cancers.